Summary

Japan Peripheral Neuropathy Market Research Report: Size, Share, Trend Analysis By Types (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, HIV/AIDS Associated Peripheral Neuropathy), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies, Others), and By End-user (Hospitals and Clinics, Ambulatory Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Market Summary:
As per Market Research Future analysis, the Japan peripheral neuropathy market size was estimated at 100.8 USD Million in 2024. The Japan peripheral neuropathy market is projected to grow from 113.97 USD Million in 2025 to 389.22 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 13.0% during the forecast period 2025 - 2035

Market Drivers:
Japan's healthcare expenditure has been on the rise, which positively impacts the peripheral neuropathy market. The government has been increasing its budget allocation for healthcare services, with spending projected to reach approximately $500 billion by 2026. This increase allows for better access to advanced treatments and medications for neuropathy. Furthermore, the introduction of new healthcare policies aims to enhance patient care and support innovative therapies. As healthcare spending continues to grow, the peripheral neuropathy market is likely to benefit from increased investment in research and development, leading to the introduction of novel treatment options and improved patient outcomes. There is a growing awareness regarding peripheral neuropathy in Japan, which serves as a significant driver for the market. Educational initiatives by healthcare professionals and organizations have led to improved recognition of symptoms and conditions associated with neuropathy. Surveys indicate that nearly 60% of the population is now more informed about the risks and management of neuropathic disorders.

Market Segment Analysis:
In the Japan peripheral neuropathy market, Diabetic Peripheral Neuropathy holds the largest market share, significantly contributing to the overall growth of the segment. This type of peripheral neuropathy is primarily associated with the rising diabetes prevalence, making it a critical area of focus for healthcare providers. Meanwhile, Chemotherapy-induced Peripheral Neuropathy is emerging with rapid growth as cancer treatments become increasingly prevalent, leading to more patients experiencing this side effect. The growth trends in the Japan peripheral neuropathy market are driven by factors such as the increasing aging population, greater awareness about diabetes and its complications, and advancements in treatment options for chemotherapy-induced cases. As healthcare systems prioritize managing these conditions, the market for these types of peripheral neuropathy is expected to expand significantly.

Regional Analysis:
The peripheral neuropathy market is currently experiencing notable developments, driven by an increasing prevalence of neuropathic conditions among the population. Factors such as diabetes, which is a significant contributor to peripheral neuropathy, are leading to a rise in demand for effective treatment options. Furthermore, advancements in medical technology and pharmaceuticals are enhancing the therapeutic landscape, providing patients with improved management solutions. The growing awareness of neuropathy symptoms and the importance of early diagnosis are also contributing to market expansion. As healthcare providers focus on personalized treatment approaches, the peripheral neuropathy market is likely to witness further growth in the coming years.

Major Players:
The following companies are key participants in the Japan Peripheral Neuropathy Market, playing a crucial role in market development through technological innovation, strategic partnerships, and competitive product offerings.

ページTOPに戻る

Table of Contents

TABLE OF CONTENT
1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
EXECUTIVE SUMMARY
Market Overview
Key Findings
Market Segmentation
Competitive Landscape
Challenges and Opportunities
Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
MARKET INTRODUCTION
Definition
Scope of the study
Research Objective
Assumption
Limitations
RESEARCH METHODOLOGY
Overview
Data Mining
Secondary Research
Primary Research
Primary Interviews and Information Gathering Process
Breakdown of Primary Respondents
Forecasting Model
Market Size Estimation
Bottom-Up Approach
Top-Down Approach
Data Triangulation
Validation
3 SECTION III: QUALITATIVE ANALYSIS
MARKET DYNAMICS
Overview
Drivers
Restraints
Opportunities
MARKET FACTOR ANALYSIS
Value chain Analysis
Porter's Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of New Entrants
Threat of Substitutes
Intensity of Rivalry
COVID-19 Impact Analysis
Market Impact Analysis
Regional Impact
Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
Japan Peripheral Neuropathy Market Segmentation
Japan Peripheral Neuropathy Market Type Outlook (USD Billion, 2019-2030)
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
Japan Peripheral Neuropathy Market Treatment Outlook (USD Billion, 2019-2030)
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange
Intravenous Immune Globulin
Others
Japan Peripheral Neuropathy Market End User Outlook (USD Billion, 2019-2030)
Hospitals and Clinics
Ambulatory Centers
Others
Japan Peripheral Neuropathy Market SECTION V: COMPETITIVE ANALYSIS
Competitive Landscape
Overview
Competitive Analysis
Market share Analysis
Major Growth Strategy in the peripheral neuropathy market
Competitive Benchmarking
Leading Players in Terms of Number of Developments in the peripheral neuropathy market
Key developments and growth strategies
New Product Launch/Service Deployment
Merger & Acquisitions
Joint Ventures
Major Players Financial Matrix
Sales and Operating Income
Major Players R&D Expenditure. 2023
Company Profiles
Astellas Pharma
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Takeda Pharmaceutical Company
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Mitsubishi Tanabe Pharma Corporation
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Daiichi Sanky
Company
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Eisai Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
On
Pharmaceutical Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Chugai Pharmaceutical Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Kyowa Kirin Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Appendix
References
Related Reports

COMPANIES MENTIONED
Astellas Pharma, Takeda Pharmaceutical Company, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd.

ページTOPに戻る

List of Tables/Graphs

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 JAPAN PERIPHERAL NEUROPATHY MARKET ANALYSIS BY TYPE
FIGURE 3 JAPAN PERIPHERAL NEUROPATHY MARKET ANALYSIS BY TREATMENT
FIGURE 4 JAPAN PERIPHERAL NEUROPATHY MARKET ANALYSIS BY END USER
FIGURE 5 KEY BUYING CRITERIA OF PERIPHERAL NEUROPATHY MARKET
FIGURE 6 RESEARCH PROCESS OF MRFR
FIGURE 7 DRO ANALYSIS OF JAPAN PERIPHERAL NEUROPATHY MARKET
FIGURE 8 DRIVERS IMPACT ANALYSIS: JAPAN PERIPHERAL NEUROPATHY MARKET
FIGURE 9 RESTRAINTS IMPACT ANALYSIS: JAPAN PERIPHERAL NEUROPATHY MARKET
FIGURE 10 SUPPLY / VALUE CHAIN: JAPAN PERIPHERAL NEUROPATHY MARKET
FIGURE 11 JAPAN PERIPHERAL NEUROPATHY MARKET, BY TYPE, 2024 (% SHARE)
FIGURE 12 JAPAN PERIPHERAL NEUROPATHY MARKET, BY TYPE, 2024 TO 2035 (USD Million)
FIGURE 13 JAPAN PERIPHERAL NEUROPATHY MARKET, BY TREATMENT, 2024 (% SHARE)
FIGURE 14 JAPAN PERIPHERAL NEUROPATHY MARKET, BY TREATMENT, 2024 TO 2035 (USD Million)
FIGURE 15 JAPAN PERIPHERAL NEUROPATHY MARKET, BY END USER, 2024 (% SHARE)
FIGURE 16 JAPAN PERIPHERAL NEUROPATHY MARKET, BY END USER, 2024 TO 2035 (USD Million)
FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS

LIST OF TABLES
LIST OF ASSUMPTIONS
Japan PERIPHERAL NEUROPATHY MARKET SIZE ESTIMATES; FORECAST
TABLE 1 BY TYPE, 2026-2035 (USD Million)
TABLE 2 BY TYPE, 2026-2035 (USD Million)
TABLE 3 BY TREATMENT, 2026-2035 (USD Million)
TABLE 4 BY TREATMENT, 2026-2035 (USD Million)
TABLE 5 BY END USER, 2026-2035 (USD Million)
TABLE 6 BY END USER, 2026-2035 (USD Million)
PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
ACQUISITION/PARTNERSHIP